Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (341-350 of 721) with videos related to

Pageof 73
Sort By:
Liver Cancer|January 23, 2026
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with BevacizumabMatthias Jeschke, Julia M Schütte, Stephan Himmen, et al.
Radiology|December 9, 2025
Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PETSungmin Woo, Benedetta Masci, Steven P Rowe, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 8, 2019
Post-radiosynovectomy imaging utilizing Erbium-169 citrateJamshid Farahati, Sandra Kazek, Ines Maric, et al.
Endocrine|September 4, 2021
Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapyHarald Lahner, Annie Mathew, Anna Lisa Klocker, et al.
EJNMMI Physics|January 3, 2024
Biodistribution and radiation dosimetry of <sup>124</sup>I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric modelsAlexandros Moraitis, Walter Jentzen, Gloria Reiter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2024
Assessment of the therapeutic efficacy of [<sup>177</sup>Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysisLudmila Santiago Almeida, Irene García Megías, Elba Cristina Sá Camargo Etchebehere, et al.
Theranostics|June 28, 2019
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumorsSusanne Lütje, Sandra Heskamp, Gerben M Franssen, et al.
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
Clinical Nuclear Medicine|February 3, 2015
SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approachR A Werner, Christina Bluemel, M Lassmann, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
Pageof 73

Showing results (341-350 of 721) with videos related to

Sort By:
Pageof 73
Liver Cancer|January 23, 2026
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with BevacizumabMatthias Jeschke, Julia M Schütte, Stephan Himmen, et al.
Radiology|December 9, 2025
Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PETSungmin Woo, Benedetta Masci, Steven P Rowe, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 8, 2019
Post-radiosynovectomy imaging utilizing Erbium-169 citrateJamshid Farahati, Sandra Kazek, Ines Maric, et al.
Endocrine|September 4, 2021
Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapyHarald Lahner, Annie Mathew, Anna Lisa Klocker, et al.
EJNMMI Physics|January 3, 2024
Biodistribution and radiation dosimetry of <sup>124</sup>I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric modelsAlexandros Moraitis, Walter Jentzen, Gloria Reiter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2024
Assessment of the therapeutic efficacy of [<sup>177</sup>Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysisLudmila Santiago Almeida, Irene García Megías, Elba Cristina Sá Camargo Etchebehere, et al.
Theranostics|June 28, 2019
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumorsSusanne Lütje, Sandra Heskamp, Gerben M Franssen, et al.
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
Clinical Nuclear Medicine|February 3, 2015
SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approachR A Werner, Christina Bluemel, M Lassmann, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
Pageof 73